Authors: Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas P

作者: Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas P

Journal: Antimicrobial Agents and Chemotherapy

期刊: 抗微生物剂与化疗学

Published: June 2006; Volume 50, Issue 6, Pages 2009-2015

出版时间: 2006年6月；第50卷，第6期，2009-2015页

DOI: 10.1128/AAC.50.6.2009-2015.2006

Abstract

The study assesses the antifungal efficacy of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a comprehensive collection of clinically significant molds and yeasts. Results indicate that posaconazole shows superior activity compared to other azoles, especially against several mold species.

摘要

该研究评估了曲安奈德、氟康唑、伊曲康唑、伏立康唑和两性霉素B对大量临床重要霉菌和酵母菌的抗真菌效果。结果表明，曲安奈德对多种霉菌的活性优于其他唑类药物。

Introduction

This paper aims to compare the in vitro activity of five antifungal agents against a broad spectrum of fungi, given the rising concern over fungal infections and the necessity for effective treatment options.

引言

本文旨在比较五种抗真菌剂对多种真菌的体外活性，鉴于真菌感染的日益严重以及对有效治疗方案的需求。

Methods

• Isolates: The study included 1,025 clinical isolates from different geographical locations.
• Testing: The minimum inhibitory concentrations (MICs) were determined using the NCCLS (National Committee for Clinical Laboratory Standards) broth microdilution method.

方法

• 分离株: 研究包括来自不同地理位置的1025个临床分离株。
• 测试: 使用NCCLS（国家临床实验室标准委员会）肉汤微量稀释法测定最小抑菌浓度（MIC）。

Results

• Yeasts: Posaconazole demonstrated the most potent activity against Candida spp. and Cryptococcus neoformans.
• Molds: It also showed superior activity against Aspergillus spp., Fusarium spp., and other rare molds.
• Comparative Analysis: Amphotericin B remained effective, but posaconazole was generally more potent than other azoles.

结果

• 酵母菌: 曲安奈德对念珠菌属和新生隐球菌表现出最强的活性。
• 霉菌: 对曲霉菌属、镰刀菌属及其他罕见霉菌也表现出优异的活性。
• 比较分析: 两性霉素B仍然有效，但曲安奈德通常比其他唑类药物更有效。

Discussion

The study highlights posaconazole as a promising antifungal agent, particularly for treating infections caused by molds and azole-resistant yeasts. The results support its use in clinical settings where broad-spectrum antifungal activity is required.

讨论

该研究强调了曲安奈德作为一种有前途的抗真菌剂，特别适用于治疗霉菌和唑类抗性酵母菌引起的感染。结果支持其在需要广谱抗真菌活性的临床环境中的使用。

Conclusion

Posaconazole exhibits strong in vitro activity against a wide array of clinically important fungi, suggesting its potential as a leading antifungal therapy.

结论

曲安奈德对多种临床重要真菌表现出强大的体外活性，表明其作为主要抗真菌治疗的潜力。

Compounds and CAS Numbers

1. Posaconazole (曲安奈德): CAS 171228-49-2

2. Fluconazole (氟康唑): CAS 86386-73-4

3. Itraconazole (伊曲康唑): CAS 84625-61-6

4. Voriconazole (伏立康唑): CAS 137234-62-9

5. Amphotericin B (两性霉素B): CAS 1397-89-3